- Home
- PCSA vs BIAF Comparison
PCSA vs BIAF Comparison
Compare PCSA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- BIAF
- Stock Information
- Founded
- PCSA 2011
- BIAF 2014
- Country
- PCSA United States
- BIAF United States
- Employees
- PCSA N/A
- BIAF N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PCSA Health Care
- BIAF Health Care
- Exchange
- PCSA Nasdaq
- BIAF Nasdaq
- Market Cap
- PCSA 12.0M
- BIAF 13.0M
- IPO Year
- PCSA N/A
- BIAF 2022
- Fundamental
- Price
- PCSA $0.32
- BIAF $2.49
- Analyst Decision
- PCSA Strong Buy
- BIAF Hold
- Analyst Count
- PCSA 1
- BIAF 1
- Target Price
- PCSA $1.00
- BIAF N/A
- AVG Volume (30 Days)
- PCSA 24.6M
- BIAF 3.3M
- Earning Date
- PCSA 11-06-2025
- BIAF 11-13-2025
- Dividend Yield
- PCSA N/A
- BIAF N/A
- EPS Growth
- PCSA N/A
- BIAF N/A
- EPS
- PCSA N/A
- BIAF N/A
- Revenue
- PCSA N/A
- BIAF $7,681,059.00
- Revenue This Year
- PCSA N/A
- BIAF N/A
- Revenue Next Year
- PCSA N/A
- BIAF $20.04
- P/E Ratio
- PCSA N/A
- BIAF N/A
- Revenue Growth
- PCSA N/A
- BIAF 4.99
- 52 Week Low
- PCSA $0.15
- BIAF $2.34
- 52 Week High
- PCSA $1.50
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- PCSA 52.55
- BIAF 46.54
- Support Level
- PCSA $0.29
- BIAF $2.43
- Resistance Level
- PCSA $0.34
- BIAF $3.50
- Average True Range (ATR)
- PCSA 0.05
- BIAF 0.29
- MACD
- PCSA -0.01
- BIAF -0.09
- Stochastic Oscillator
- PCSA 27.62
- BIAF 5.69
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.